Connor Clark & Lunn Investment Management Ltd. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 940.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,901 shares of the biopharmaceutical company’s stock after purchasing an additional 11,661 […]